ethyl 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate | 869296-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: ethyl 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate
• 英文别名: ethyl 4-oxo-3H,4H-pyrido[3,4-d]pyrimidine-2-carboxylate；Ethyl 4-oxo-1,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate；ethyl 4-oxo-3H-pyrido[3,4-d]pyrimidine-2-carboxylate
• CAS: 869296-21-9
• 化学式: C₁₀H₉N₃O₃
• 分子量: 219.2
• InChiKey: CILMXDLNTUCWNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-甲氧基苄胺 、 ethyl 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 N-[(3-methoxyphenyl)methyl]-4-oxo-3H,4H-pyrido[3,4-d]pyrimidine-2-carboxamide
  参考文献：
  名称：

  Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site

  摘要：

  On the basis of X-ray co-crystal structures of matrix metalloproteinase-13 (MMP-13) in complex with its inhibitors, our structure-based drug design (SBDD) strategy was directed to achieving high affinity through optimal protein-ligand interaction with the unique S1 '' hydrophobic specificity pocket. This report details the optimization of lead compound 44 to highly potent and selective MMP-13 inhibitors based on fused pyrimidine scaffolds represented by the thienopyrimidin-4-one 26c. Furthermore, we have examined the release of collagen fragments from bovine nasal cartilage in response to a combination of IL-1 and oncostatin M. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2014.07.025
• 作为产物：
  描述：

  3,4-吡啶二酰亚胺 在 吡啶 、 草酰氯 、 氨 、 溴 、 sodium ethanolate 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 19.67h， 生成 ethyl 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate
  参考文献：
  名称：

  SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

  摘要：

  本发明提供了一种新型酰胺衍生物，具有基质金属蛋白酶抑制活性，并且作为药用剂是有用的，该化合物由以下式(I)表示，其中环A是一个可选择取代的含氮杂环，环B是一个可选择取代的单环同核环或可选择取代的单环杂环，Z是N或NR1（R1是氢原子或可选择取代的碳氢基团），是一个单键或双键，R2是氢原子或可选择取代的碳氢基团，X是一个具有1到6个原子的可选择取代的间隔物，环C是（1）一个可选择取代的同核环或（2）一个除了由（II）表示的环之外的可选择取代的杂环（X′是S、O、SO或CH2），并且环B和环C中至少有一个有取代基，但不包括N-{(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺，或其盐。

  公开号：

  US20150329556A1

文献信息

• Heterobicyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080261968A1

  公开（公告）日：2008-10-23

  The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.

  本发明涉及含有杂环的药物，特别是含有杂环的金属蛋白酶抑制剂。更具体地说，本发明提供了一种新型的杂环MMP-3、MMP-8和/或MMP-13抑制剂，其在与当前已知的MMP-13、MMP-8和MMP-3抑制剂相比具有更高的效力和选择性。
• HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1740551B1

  公开（公告）日：2012-09-12
• Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio)
  申请人：Terauchi Jun

  公开号：US20080027050A1

  公开（公告）日：2008-01-31

  The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]-2-hydroxypropyl}-5,6-dimethyl-4-oxo-1,4-dihadrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.
• US7713966B2
  申请人：——

  公开号：US7713966B2

  公开（公告）日：2010-05-11
• US9212149B2
  申请人：——

  公开号：US9212149B2

  公开（公告）日：2015-12-15